<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>Vioela Respress — Articles &amp; Blog</title><description>Twelve years in pharmaceutical and biotech quality, eight of them at FDA leading GMP inspections. I help sponsors and manufacturers get inspection-ready, and fix what an inspection would find.</description><link>https://vioelarespress.com</link><language>en-us</language><item><title>What stands between you and a sterility failure</title><link>https://vioelarespress.com/articles/controls-that-stand-between-you-and-a-sterility-failure</link><guid isPermaLink="true">https://vioelarespress.com/articles/controls-that-stand-between-you-and-a-sterility-failure</guid><description>A working list of the controls that keep sterile product sterile, sorted by class, with how each one fails and what FDA has said about it in warning letters issued during 2026.</description><pubDate>Tue, 10 Nov 2026 00:00:00 GMT</pubDate><category>Articles</category><category>investigations</category><category>fda</category><category>quality-systems</category><category>aseptic</category></item><item><title>The investigation they should have run</title><link>https://vioelarespress.com/articles/the-investigation-they-should-have-run</link><guid isPermaLink="true">https://vioelarespress.com/articles/the-investigation-they-should-have-run</guid><description>A reconstruction built on one public warning letter: recurring sterility failures blamed on operators, an airflow problem found by the regulator instead, and a step by step account of who you would actually need to talk to, in what order, to reach the real cause.</description><pubDate>Tue, 10 Nov 2026 00:00:00 GMT</pubDate><category>Articles</category><category>investigations</category><category>capa</category><category>fda</category><category>quality-systems</category></item><item><title>Human error is not a root cause</title><link>https://vioelarespress.com/articles/human-error-is-not-a-root-cause</link><guid isPermaLink="true">https://vioelarespress.com/articles/human-error-is-not-a-root-cause</guid><description>Inadequate investigation is one of the most consistently cited findings in FDA inspections, and the problem is rarely that firms do not investigate. A walk through the mechanism stage by stage, the decisions each stage forces, and the defects that get records sent back.</description><pubDate>Mon, 09 Nov 2026 00:00:00 GMT</pubDate><category>Articles</category><category>investigations</category><category>capa</category><category>fda</category><category>quality-systems</category></item><item><title>What I write about, and why</title><link>https://vioelarespress.com/blog/what-i-write-about</link><guid isPermaLink="true">https://vioelarespress.com/blog/what-i-write-about</guid><description>A short note on the difference between the Articles section and this one, and what I am trying to be useful about.</description><pubDate>Mon, 02 Nov 2026 00:00:00 GMT</pubDate><category>Blog</category><category>notes</category></item><item><title>Somewhere in industry, a chatbot just got blamed for a warning letter</title><link>https://vioelarespress.com/blog/delegation-with-vibes</link><guid isPermaLink="true">https://vioelarespress.com/blog/delegation-with-vibes</guid><description>FDA cited a firm that relied on AI for GMP documentation and then said it did not know process validation was required, because the AI never mentioned it.</description><pubDate>Thu, 28 May 2026 00:00:00 GMT</pubDate><category>Blog</category><category>ai</category><category>gmp</category><category>fda</category></item><item><title>Do not manage the clock. Manage the risk.</title><link>https://vioelarespress.com/articles/one-day-inspections</link><guid isPermaLink="true">https://vioelarespress.com/articles/one-day-inspections</guid><description>FDA’s one-day inspectional assessments are not a shorter inspection. They are a faster decision about whether your site deserves a longer one.</description><pubDate>Wed, 20 May 2026 00:00:00 GMT</pubDate><category>Articles</category><category>inspections</category><category>fda</category><category>readiness</category></item><item><title>Harmonisation is a business strategy, not an afterthought</title><link>https://vioelarespress.com/articles/harmonising-quality-across-markets</link><guid isPermaLink="true">https://vioelarespress.com/articles/harmonising-quality-across-markets</guid><description>Growing companies treat FDA, EU and local requirements as three different languages. They are closer than they look, and building to the highest standard first is cheaper than retrofitting.</description><pubDate>Tue, 12 May 2026 00:00:00 GMT</pubDate><category>Articles</category><category>quality-systems</category><category>eu-gmp</category><category>fda</category><category>scale-up</category></item><item><title>The GLP-1 story is not about telehealth. It is about distribution.</title><link>https://vioelarespress.com/articles/the-glp-1-architecture</link><guid isPermaLink="true">https://vioelarespress.com/articles/the-glp-1-architecture</guid><description>Four layers, one patient experience, and an architecture FDA has seen before. Once it looks like a system distributing drugs, the FDCA stops caring how the contracts are structured.</description><pubDate>Wed, 22 Apr 2026 00:00:00 GMT</pubDate><category>Articles</category><category>enforcement</category><category>fda</category><category>compounding</category></item><item><title>Clarity enables compliance. Ambiguity drives overcompliance.</title><link>https://vioelarespress.com/articles/ambiguity-drives-overcompliance</link><guid isPermaLink="true">https://vioelarespress.com/articles/ambiguity-drives-overcompliance</guid><description>FDA’s cybersecurity guidance for medical devices is strong on principle and fuzzy on threshold. That gap does not reduce burden. It moves the interpretation downstream, and companies overbuild to defend themselves.</description><pubDate>Wed, 15 Apr 2026 00:00:00 GMT</pubDate><category>Articles</category><category>medical-devices</category><category>fda</category><category>cybersecurity</category><category>guidance</category></item><item><title>The cleanroom is the easy part</title><link>https://vioelarespress.com/blog/the-cleanroom-is-the-easy-part</link><guid isPermaLink="true">https://vioelarespress.com/blog/the-cleanroom-is-the-easy-part</guid><description>Asked how long it takes to go from nothing to GMP production, a lot of people answer three to six months. That is the answer to a different question.</description><pubDate>Fri, 10 Apr 2026 00:00:00 GMT</pubDate><category>Blog</category><category>quality-systems</category><category>readiness</category><category>scale-up</category></item><item><title>AI is coming to the GMP quality system. Understanding has to come first.</title><link>https://vioelarespress.com/articles/ai-in-gmp-manufacturing</link><guid isPermaLink="true">https://vioelarespress.com/articles/ai-in-gmp-manufacturing</guid><description>FDA has a planned guidance on AI and machine learning in pharmaceutical manufacturing. Having evaluated process analytical technology from the inside, I think the hard part is not the model. It is the signature underneath it.</description><pubDate>Wed, 08 Apr 2026 00:00:00 GMT</pubDate><category>Articles</category><category>ai</category><category>gmp</category><category>fda</category><category>quality-systems</category></item><item><title>The regulatory door just opened for new approach methodologies</title><link>https://vioelarespress.com/articles/new-approach-methodologies</link><guid isPermaLink="true">https://vioelarespress.com/articles/new-approach-methodologies</guid><description>FDA’s draft guidance on non-animal methods runs on two principles: context of use and weight of evidence. Together they tell you exactly where a predictive model is allowed to sit.</description><pubDate>Mon, 06 Apr 2026 00:00:00 GMT</pubDate><category>Articles</category><category>fda</category><category>guidance</category><category>drug-development</category><category>ai</category></item><item><title>A thinking tool, not a decision tool</title><link>https://vioelarespress.com/articles/a-thinking-tool-not-a-decision-tool</link><guid isPermaLink="true">https://vioelarespress.com/articles/a-thinking-tool-not-a-decision-tool</guid><description>Virtual cell models trained on causal perturbation data are a real scientific step up. Looked at from a regulatory perspective, they still sit upstream of anything FDA would accept as evidence.</description><pubDate>Sun, 05 Apr 2026 00:00:00 GMT</pubDate><category>Articles</category><category>ai</category><category>drug-development</category><category>fda</category></item><item><title>If the signal is X, where does the risk live?</title><link>https://vioelarespress.com/articles/signal-based-qmsr-inspection-framework</link><guid isPermaLink="true">https://vioelarespress.com/articles/signal-based-qmsr-inspection-framework</guid><description>A generic, teaching-only framework for thinking about signal-based QMSR inspections: where an investigator is likely to enter the quality system, and the lifecycle path they may follow from there.</description><pubDate>Fri, 03 Apr 2026 00:00:00 GMT</pubDate><category>Articles</category><category>medical-devices</category><category>qmsr</category><category>inspections</category><category>readiness</category></item><item><title>QMSR aligns the rules. The bigger change is how inspections will feel.</title><link>https://vioelarespress.com/articles/qmsr-changes-how-inspections-feel</link><guid isPermaLink="true">https://vioelarespress.com/articles/qmsr-changes-how-inspections-feel</guid><description>Everyone is discussing the ISO 13485 alignment. The more consequential shift is from QSIT’s four subsystems to following a product risk across the device lifecycle.</description><pubDate>Wed, 01 Apr 2026 00:00:00 GMT</pubDate><category>Articles</category><category>medical-devices</category><category>qmsr</category><category>inspections</category><category>fda</category></item></channel></rss>